EXEL Long Call Strategy
EXEL (Exelixis, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer, primarily focusing on the identification, advancement, and marketing of novel oncological treatments within the United States. Its portfolio of commercially available therapeutics includes CABOMETYX tablets, prescribed for individuals with advanced renal cell carcinoma who have previously undergone anti-angiogenic treatment, and COMETRIQ capsules, utilized for managing progressive and metastatic medullary thyroid cancer. Both CABOMETYX and COMETRIQ originate from cabozantinib, a compound that inhibits several tyrosine kinases such as MET, AXL, RET, and VEGF receptors. Additionally, Exelixis offers COTELLIC, an MEK inhibitor employed in combination therapies for advanced melanoma, and MINNEBRO, an orally administered, non-steroidal selective mineralocorticoid receptor blocker, approved for hypertension treatment in Japan. The company's developmental pipeline features several promising candidates, such as XL092, an oral tyrosine kinase inhibitor designed to target VEGF receptors, MET, AXL, MER, and other kinases crucial for cancer proliferation; XB002, an antibody-drug conjugate containing a human monoclonal antibody against tissue factor (TF), intended for advanced solid tumors and non-Hodgkin's lymphoma; and XL102, an orally available cyclin-dependent kinase 7 (CDK7) inhibitor being developed for advanced or metastatic solid tumors. Exelixis, Inc. maintains extensive research partnerships and licensing arrangements with numerous pharmaceutical and biotechnology entities, including Ipsen Pharma SAS, Takeda Pharmaceutical Company Ltd., F.
EXEL (Exelixis, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $12.88B, a trailing P/E of 14.93, a beta of 0.42 versus the broader market, a 52-week range of 33.76-57.57, average daily share volume of 2.7M, a public-listing history dating back to 2000, approximately 1K full-time employees. These structural characteristics shape how EXEL stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.42 indicates EXEL has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.
What is a long call on EXEL?
A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.
EXEL snapshot
As of August 14, 2026, spot at $51.09, ATM IV 32.90%, IV rank 32.64%, expected move 9.43%. The long call on EXEL below is built from the August 14, 2026 end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 7-day expiry.
Why this long call structure on EXEL specifically: EXEL IV at 32.90% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 9.43% (roughly $4.82 on the underlying). The 7-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated EXEL expiries trade a higher absolute premium for lower per-day decay. Position sizing on EXEL should anchor to the underlying notional of $51.09 per share and to the trader's directional view on EXEL stock.
EXEL long call setup
The EXEL long call below is built from the August 14, 2026 end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With EXEL at $51.09 on that close, the first option leg uses a $50.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed EXEL chain at a 7-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 EXEL shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $50.00 | $1.30 |
EXEL long call risk and reward
- Net Premium / Debit
- -$130.00
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- -$130.00
- Breakeven(s)
- $51.30
- Risk / Reward Ratio
- Unbounded
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.
EXEL long call payoff curve
Modeled P&L at expiration across a range of underlying prices for the long call on EXEL. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -100.0% | -$130.00 |
| $11.31 | -77.9% | -$130.00 |
| $22.60 | -55.8% | -$130.00 |
| $33.90 | -33.7% | -$130.00 |
| $45.19 | -11.5% | -$130.00 |
| $56.49 | +10.6% | +$518.59 |
| $67.78 | +32.7% | +$1,648.11 |
| $79.08 | +54.8% | +$2,777.62 |
| $90.37 | +76.9% | +$3,907.14 |
| $101.67 | +99.0% | +$5,036.66 |
When traders use long call on EXEL
Long calls on EXEL express a bullish thesis with defined risk; traders use them ahead of EXEL catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
EXEL thesis for this long call
The market-implied 1-standard-deviation range for EXEL extends from approximately $46.27 on the downside to $55.91 on the upside. A EXEL long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current EXEL IV rank near 32.64% is mid-range against its 1-year distribution, so the IV signal is neutral; the long call thesis on EXEL should anchor more to the directional view and the expected-move geometry. As a Healthcare name, EXEL options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to EXEL-specific events.
EXEL long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. EXEL positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move EXEL alongside the broader basket even when EXEL-specific fundamentals are unchanged. Long-premium structures like a long call on EXEL are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current EXEL chain quotes before placing a trade.
Frequently asked questions
- What is a long call on EXEL?
- A long call on EXEL is the long call strategy applied to EXEL (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With EXEL stock at $51.09 on the August 14, 2026 close, the strikes shown on this page are snapped to the nearest listed EXEL chain strike and the premiums come straight from that session's bid/ask midpoint.
- How are EXEL long call max profit and max loss calculated?
- Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the EXEL long call priced from the August 14, 2026 end-of-day chain at a 30-day expiry (ATM IV 32.90%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$130.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a EXEL long call?
- The breakeven for the EXEL long call priced on this page is roughly $51.30 at expiration, derived from the August 14, 2026 end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The EXEL market-implied 1-standard-deviation expected move in the same options snapshot is approximately 9.43%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a long call on EXEL?
- Long calls on EXEL express a bullish thesis with defined risk; traders use them ahead of EXEL catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
- How does current EXEL implied volatility affect this long call?
- EXEL ATM IV is at 32.90% with IV rank near 32.64%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.